Fangzhou ’XingShi’ Large Language Model Highlighted Among China’s Most Anticipated Healthcare Models for 2026
Source: GlobeNewswireSHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Industry research platform VBData recently highlighted “XingShi” Large Language Model (“XS LLM”) from Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, as one of China’s most anticipated healthcare AI models for 2026.
The “XingShi” Large Language Model (“XS LLM”) integrates five intelligent agents — knowledge services, triage, pre-consultation, physician support and electronic medical records — into a closed-loop system covering the full chronic disease management cycle, an approach that has drawn international attention including coverage by Nature.
As one of the earliest domestic models developed alongside the emergence of OpenEvidence, XS LLM is powered by more than 1.1 million articles from over 170 core journals from the database of the Chinese Medical Association, spanning all major clinical disciplines. VBData estimates the model has delivered nearly 400,000 instances of technical assistance to physicians, marking it as a significant tool for clinical support and professional workflows.
Built as the “core digital brain” of Fangzhou’s platform, XS LLM powers five AI-enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search. Each product addresses distinct clinical and patient-side use cases, enabling real-time, precision interventions across medication guidance, patient education, diagnostic assistance, and medical reference.
XS LLM was previously featured by Nature News section under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?”, and the article explored the model’s development, alongside expert views on its potential impact for improving chronic disease management.
Other models cited by VBData include offerings from JD Health, Ant Group and Tencent Health. VBData noted that leading domestic medical AI models are increasingly optimized for China-specific clinical guidelines, reimbursement frameworks and regulatory requirements in order to meet to meet ambitious national targets for broad development of medical AI models by 2027 and near-universal intelligent clinical assistance in primary care by 2030.
Looking ahead, Fangzhou will continue to deepen AI integration across chronic disease services, and broaden access to professional, technology-enabled care while reinforcing its position as a key player in the country’s healthcare digitization drive.
About VBData
Founded in 2014, VBData is an industry information accelerator platform that builds a business case library through in-depth analysis, deconstructs sectors with systematic research, and fosters industry collaboration through dedicated services.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
